Dolutegravir

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infection, Human Immunodeficiency Virus

Conditions

Infection, Human Immunodeficiency Virus

Trial Timeline

Jan 1, 2012 → May 1, 2014

About Dolutegravir

Dolutegravir is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01499199. Target conditions include Infection, Human Immunodeficiency Virus.

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01499199Phase 3Completed
NCT01328041Phase 3Completed

Competing Products

20 competing products in Infection, Human Immunodeficiency Virus

See all competitors
ProductCompanyStageHype Score
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1944ModernaPhase 1
0
mRNA-1189ModernaPhase 2
0
mRNA-1647ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0
mRNA-1195.1ModernaPhase 1
0
mRNA-1647ModernaPhase 1
0
mRNA-1647ModernaPhase 3
0
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
BSG005Alkem LaboratoriesPhase 1/2
39
Zotatifin + PlaceboeFFECTOR TherapeuticsPhase 1
19
AAVLP-HPV + Placebo2A PharmaPhase 1
19
CT-P59CelltrionPhase 1
29
CT-P63 + PlaceboCelltrionPhase 1
29